These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 33314508

  • 1. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
    Chan WYK, Kwok JSY, Chiang AKS, Chan GCF, Lee PPW, Ha SY, Cheuk DKL.
    Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
    [Abstract] [Full Text] [Related]

  • 2. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.
    Brodszki N, Turkiewicz D, Toporski J, Truedsson L, Dykes J.
    Orphanet J Rare Dis; 2016 Jan 15; 11():5. PubMed ID: 26768987
    [Abstract] [Full Text] [Related]

  • 3. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
    Koster EAS, von dem Borne PA, van Balen P, van Egmond EHM, Marijt EWA, Veld SAJ, Jedema I, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, de Wreede LC, Halkes CJM.
    Transplant Cell Ther; 2023 Apr 15; 29(4):268.e1-268.e10. PubMed ID: 36587743
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
    Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC.
    Front Immunol; 2024 Apr 15; 15():1335341. PubMed ID: 38545096
    [Abstract] [Full Text] [Related]

  • 5. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients.
    Chen H, Li XY, Zhan LP, Fang JP, Huang K, Li Y, Weng WJ, Xu LH, Xu HG, Zhou DH.
    Pediatr Transplant; 2020 Dec 15; 24(8):e13876. PubMed ID: 33098346
    [Abstract] [Full Text] [Related]

  • 6. Immunohematologic reconstitution in pediatric patients after T cell-depleted HLA-haploidentical stem cell transplantation for thalassemia.
    Isgrò A, Marziali M, Sodani P, Gaziev J, Erer B, Polchi P, Paciaroni K, Roveda A, De Angelis G, Gallucci C, Alfieri C, Simone MD, Zinno F, Isacchi G, Adorno G, Lanti A, Leti W, Aiuti F, Fraboni D, Andreani M, Lucarelli G.
    Biol Blood Marrow Transplant; 2010 Nov 15; 16(11):1557-66. PubMed ID: 20546907
    [Abstract] [Full Text] [Related]

  • 7. Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial.
    Maschan M, Blagov S, Shelikhova L, Shekhovtsova Z, Balashov D, Starichkova J, Kurnikova E, Boyakova E, Muzalevskii Y, Kazachenok A, Trakhtman P, Osipova E, Khripkova N, Zhogov V, Novichkova G, Maschan A.
    Bone Marrow Transplant; 2018 Mar 15; 53(3):264-273. PubMed ID: 29269793
    [Abstract] [Full Text] [Related]

  • 8. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
    Karasu GT, Yesilipek MA, Karauzum SB, Uygun V, Manguoglu E, Kupesiz A, Hazar V.
    Pediatr Blood Cancer; 2012 Mar 15; 58(3):453-8. PubMed ID: 21990066
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.
    JAMA; 2014 Jul 02; 312(1):48-56. PubMed ID: 25058217
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C, Wadhera K, Breslin P, Pearce R, Wells M, Alajangi R, Protheroe R, Marks DI, Griffin J, Robinson S.
    Biol Blood Marrow Transplant; 2020 Dec 02; 26(12):2271-2278. PubMed ID: 32890747
    [Abstract] [Full Text] [Related]

  • 13. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.
    Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Satayasai W, Sirireung S, Sruamsiri R, Wahidiyat PA, Ungkanont A, Issaragrisil S, Andersson BS.
    Bone Marrow Transplant; 2016 Jun 02; 51(6):813-8. PubMed ID: 26878659
    [Abstract] [Full Text] [Related]

  • 14. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.
    Biol Blood Marrow Transplant; 2000 Jun 02; 6(3A):309-20. PubMed ID: 10905768
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.
    Shook DR, Triplett BM, Eldridge PW, Kang G, Srinivasan A, Leung W.
    Pediatr Blood Cancer; 2015 Apr 02; 62(4):666-73. PubMed ID: 25559618
    [Abstract] [Full Text] [Related]

  • 17. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
    Bashey A, Solomon SR.
    Bone Marrow Transplant; 2014 Aug 02; 49(8):999-1008. PubMed ID: 24842530
    [Abstract] [Full Text] [Related]

  • 18. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2003 May 02; 9(5):320-9. PubMed ID: 12766882
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
    Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.
    Biol Blood Marrow Transplant; 2015 Feb 02; 21(2):288-92. PubMed ID: 25464116
    [Abstract] [Full Text] [Related]

  • 20. Donor Lymphocyte Infusion-Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation.
    Duran-Struuck R, Matar AJ, Crepeau RL, Teague AGS, Horner BM, Pathiraja V, Spitzer TR, Fishman JA, Bronson RT, Sachs DH, Huang CA.
    Biol Blood Marrow Transplant; 2016 Nov 02; 22(11):1953-1960. PubMed ID: 27543159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.